Condition: Steroid-refractory Acute Graft Versus Host Disease · Sponsor: Novartis Pharmaceuticals
The purpose of this study is to assess the efficacy and safety of ruxolitinib therapy in Chinese adults and adolescents (≥ 12 years old) with Grade II-IV steroid-refractory acute graft versus host disease (SR-aGvHD).
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Novartis Pharmaceuticals
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Guangzhou, Guangdong, China | Recruiting |
| Novartis Investigative Site | Guangzhou, Guangdong, China | Recruiting |
| Novartis Investigative Site | Zhengzhou, Henan, China | Recruiting |
| Novartis Investigative Site | Wuhan, Hubei, China | Recruiting |
| Novartis Investigative Site | Changchun, Jilin, China | Recruiting |
| Novartis Investigative Site | Xian, Shanxi, China | Recruiting |
| Novartis Investigative Site | Chengdu, Sichuan, China | Recruiting |
| Novartis Investigative Site | Hangzhou, Zhejiang, China | Recruiting |
| Novartis Investigative Site | Beijing, China | Recruiting |
| Novartis Investigative Site | Beijing, China | Recruiting |
| Novartis Investigative Site | Beijing, China | Recruiting |
| Novartis Investigative Site | Beijing, China | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06462469